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rTATE-OF-THE-ART PAPER1925The Obesity Paradoxarl J. Lavie, Richard V. Milani, Hector O. Ventura
avie and colleagues review the relationships between obesity and cardiovascular (CV) disease
nd outcomes. This is especially important now as obesity has reached global epidemic
roportions and has been associated with numerous comorbidities. Despite the effects of
besity, numerous studies have documented an “obesity paradox” in that overweight and
bese subjects with established CV disease have a better prognosis than nonoverweight/
onobese patients. This review delves into the obesity paradox and concludes by examining
hether weight loss, either through surgery or exercise, should be recommended to all obese
atients.CARDIAC
RESYNCHRONIZATION THERAPYIEWPOINT1933Noninvasive Imaging Will Identify Nonresponders to CRTeroen J. Bax, John Gorcsan III
n the first of 3 related articles regarding the issue of which patients with systolic dysfunction
re likely to benefit from cardiac resynchronization therapy (CRT), Bax and Gorcsan review
he large body of published evidence that has demonstrated that certain echocardiographic
easures of left ventricular dyssynchrony can predict a response to CRT. They agree
hat the PROSPECT study was flawed by lax patient selection and technical factors with
chocardiographic data acquisition and analysis. CRT is undeniably a beneficial therapy
o a large number of heart failure patients who are selected properly. Refinements in the
echnical aspects of data acquisition and analysis along with a greater understanding of
athophysiology will continue to refine the selection of CRT patients.TATE-OF-THE-ART PAPER1944Selection Criteria for CRT: QRS Is the Gold Standardathaniel M. Hawkins, Mark C. Petrie, Malcolm I. Burgess, John J. V. McMurray
awkins and colleagues argue that a lengthened QRS is the only parameter that has been
roven in large-scale trials with hard end points. Several echocardiographic indexes are
eviewed in detail, with the common shortcoming that most lack reproducibility or validation
n appropriately sized trials. They conclude that the electrocardiogram remains a simple,
nexpensive, and reproducible tool that identifies patients likely to benefit from cardiac
esynchronization therapy (CRT). Patient selection outside of clinical trials must use the onlyparameter that has been prospectively validated in landmark clinical trials.(continued on page A-29)
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cOMMENTARY1960The QRS Should Not Be the Only Parameter to Determine Eligibility for CRTohn E. Sanderson
n a counterpoint to the article by Hawkins and colleagues, Sanderson asserts that
any of the patients with a widened QRS do not derive any benefit from cardiac
esynchronization therapy (CRT). Furthermore, there is a real potential for harm to
hese patients, either during the device implantation or from the actions of the
evice. For Dr. Sanderson, the failure of the PROSPECT trial was not a failure of
mage-based guidance for CRT implantation, but rather due to faulty design of the
tudy that resulted in poor-quality echocardiographic studies in a large proportion of
he subjects. In summary, not all patients implanted with CRT devices improve, and
here is an imperative to improve the selection criteria to prevent harm being done.CLINICAL RESEARCH CUTE CORONARY SYNDROMES1965Upstream Clopidogrel Improves Outcomes, Even in Those Who Go On to CABGEditorial Comment
Colin M. Barker,amin Ebrahimi, Cornelius Dyke, Roxana Mehran, Steven V. Manoukian, Frederick Feit, David A. Cox,
ernard J. Gersh, E. Magnus Ohman, Harvey D. White, Jeffrey W. Moses, James H. Ware,
. Michael Lincoff, Gregg W. Stone
brahimi and colleagues reanalyzed data from the ACUITY trial for the subset of patients
ho went on to coronary artery bypass grafting (CABG). In this trial, the timing and use of
lopidogrel was per investigator discretion; for those who received clopidogrel, a 5-day
ashout period prior to CABG was recommended. Eleven percent of the trial subjects
nderwent CABG prior to discharge, and approximately one-half of these received
lopidogrel prior to angiography. By multivariable analysis, clopidogrel use prior to CABG
educed 30-day composite ischemia (odds ratio [OR]: 0.67) but did not increase post-CABG
ajor bleeding (OR: 0.98). Clopidogrel administration prior to catheterization is strongly
ssociated with fewer adverse ischemic events without significantly increasing bleeding risks.
hese findings support the American College of Cardiology/American Heart Association
uidelines for upstream clopidogrel administration in all patients with non–ST-segment
levation acute coronary syndromes.EART FAILURE
1975ncreased Chemosensitivity to Hypoxia and
Hypercapnia Predicts Worse Outcomes in Patients With HFlberto Giannoni, Michele Emdin, Francesca Bramanti, Giovanni Iudice, Darrel P. Francis, Antonio Barsotti,
assimo Piepoli, Claudio Passino
iannoni and colleagues evaluated the importance of chemosensitivity to hypoxia and
ypercapnia in patients with systolic heart failure (HF). Chemosensitivity to hypoxia
s defined as an exaggerated increase in minute ventilation during hypoxemia, and
hemosensitivity to hypercapnia is similarly defined. At baseline, 28% of subjects had
nhanced chemosensitivity to both hypoxia and hypercapnia. Despite similar ejection
ractions, chemosensitive patients were more symptomatic and had higher plasma
rain natriuretic peptide and norepinephrine levels, more Cheyne-Stokes respiration,
nd more ventricular arrhythmias. Four-year survival was only 49% in chemosensitive
atients compared with 100% for patients with normal chemosensitivity. Increased
hemosensitivity to both hypoxia and hypercapnia is an adverse prognostic marker in HF.
(continued on page A-32)
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iARDIAC IMAGING
1981schemia by Exercise Echocardiography Predicts
Adverse Risk in Patients With Normal Exercise ECGsEditorial Comment
Frank A. Flachskampf,lberto Bouzas-Mosquera, Jesús Peteiro, Nemesio Álvarez-Garcı´a, Francisco J. Broullo´n, Victor X. Mosquera,
ourdes Garcı´a-Bueno, Luis Ferro, Alfonso Castro-Beiras
ouzas-Mosquera and colleagues studied whether or not ischemia detectable by exercise
chocardiography (EE) but not by exercise electrocardiography (ECG) predicted adverse
utcomes. The wall motion score index was calculated at rest and during exercise for over
,000 subjects who did not have chest pain or ECG changes during exercise. Nearly 17% of
his cohort had evidence of inducible ischemia. Compared with patients with no ischemia,
hese subjects were approximately twice as likely to die or to suffer a major adverse cardiac
vent (MACE) during 4.5 years of follow-up. EE provides significant prognostic information
or predicting mortality and MACE in patients with interpretable ECG and normal exercise
CG testing.PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH
1993antrolene May Improve the Function of Failing
Cardiomyocytes by Stabilizing the Ryanodine ReceptorEditorial Comment
Thomas R. Shannon,higeki Kobayashi, Masafumi Yano, Takeshi Suetomi, Makoto Ono, Hiroki Tateishi, Mamoru Mochizuki,
iaojuan Xu, Hitoshi Uchinoumi, Shinichi Okuda, Takeshi Yamamoto, Noritaka Koseki, Hiroyuki Kyushiki,
oriaki Ikemoto, Masunori Matsuzaki
obayashi and colleagues investigated the effect of dantrolene on calcium release and
ardiomyocyte function in failing hearts. Sarcoplasmic reticulum (SR) vesicles and
ardiomyocytes were isolated from dogs with either normal function or after the induction of
apid ventricular pacing-induced heart failure (HF). In the SR isolated from HF hearts, the
yanodine receptor (RyR) was found to have defective interdomain interactions, otherwise
nown as domain unzipping, which caused spontaneous Ca2 leaks. Dantrolene suppressed
oth domain unzipping and the Ca2 leak. Dantrolene corrects defective interdomain
nteractions within RyR in failing hearts and may have the potential to treat HF.
